Response to Third Dose of Vaccine Against SARS-CoV-2 in Adolescent and Young Adult Kidney Transplant Recipients

The response to mRNA vaccines against SARS-CoV-2 has been shown to be better in adolescents and young adults than adults.1 Kidney transplant recipients (KTRs) show a suboptimal response to mRNA vaccines compared with the general population because of immunosuppressive therapy,2 and a third dose is suggested to boost immune response in KTRs.3 Neutralizing antibodies (anti–receptor binding domain [anti-RBD]) were demonstrated to predict protection against symptomatic infection.4 However, reports on adolescent and young adult KTRs are scarce and mostly based on total antispike (anti-S) immunoglobulin G (IgG) detection.5 We report the response profile in this population completing the vaccine schedule.